
|Articles|August 28, 2014
- Head and Neck Cancers (Issue 1)
- Volume 1
- Issue 1
Results of the SELECT Trial in Thyroid Cancer
Author(s)Martin Schlumberger, MD
Martin Schlumberger, MD, Institut Gustave Roussy, Villejuif Cedex, professor of oncology, University Paris-Sud, France, discusses the takeaway points for a community oncologist from the SELECT trial.
Advertisement
Martin Schlumberger, MD, Institut Gustave Roussy, Villejuif Cedex, professor of oncology, University Paris-Sud, France, discusses the takeaway points for a community oncologist from the SELECT trial.
Learn more about targeted agents and radioactive iodine resistance > >
Articles in this issue
over 11 years ago
Unmet Needs in the Treatment of Thyroid Cancerover 11 years ago
Immunotherapy in Head and Neck Cancersover 11 years ago
Molecular Markers Emerge in the Diagnosis of Thyroid Cancerover 11 years ago
Update on Targeted Therapies in Head and Neck CancersAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5







































